TY - JOUR
T1 - Risk of repeated febrile episodes during chemotherapy-induced granulocytopenia in children with cancer
T2 - A prospective single center study
AU - Bagnasco, Francesca
AU - Haupt, Riccardo
AU - Fontana, Vincenzo
AU - Valsecchi, Maria Grazia
AU - Rebora, Paola
AU - Caviglia, Ilaria
AU - Caruso, Silvia
AU - Castagnola, Elio
PY - 2012/6
Y1 - 2012/6
N2 - Background: Febrile neutropenia (FN) is a possible complication of antineoplastic chemotherapy. Aim of the study was to estimate the risk of developing fever at the beginning of any neutropenic period based on the previous history of FN. Procedure: The conditional frailty model was used to estimate the risk of developing fever during neutropenia separately for children with acute leukaemia/non-Hodgkin lymphoma (AL/NHL), or solid tumour (ST). The total number of previous FN episodes (PFNE), age, gender, type of tumour, calendar year of granulocytopenic period, phase of treatment, and granulocyte count were included in the model. Results: A total of 901 granulocytopenic periods was observed in 223 children: 306 in 66 AL/NHL and 595 in 157 ST. Fever developed in 328 cases: 125 in 53 AL/NHL and 203 in 92 ST. The PFNE variable was not significantly associated to the risk of fever [hazard ratio (HR) of 0.87, 95% confidence interval (CI) of 0.62-1.22 in children with AL/NHL, and HR of 0.98, 95% CI of 0.70-1.37 in those with ST]. The hazard of FN was significantly affected by the phase of treatment in AL/NHL (P
AB - Background: Febrile neutropenia (FN) is a possible complication of antineoplastic chemotherapy. Aim of the study was to estimate the risk of developing fever at the beginning of any neutropenic period based on the previous history of FN. Procedure: The conditional frailty model was used to estimate the risk of developing fever during neutropenia separately for children with acute leukaemia/non-Hodgkin lymphoma (AL/NHL), or solid tumour (ST). The total number of previous FN episodes (PFNE), age, gender, type of tumour, calendar year of granulocytopenic period, phase of treatment, and granulocyte count were included in the model. Results: A total of 901 granulocytopenic periods was observed in 223 children: 306 in 66 AL/NHL and 595 in 157 ST. Fever developed in 328 cases: 125 in 53 AL/NHL and 203 in 92 ST. The PFNE variable was not significantly associated to the risk of fever [hazard ratio (HR) of 0.87, 95% confidence interval (CI) of 0.62-1.22 in children with AL/NHL, and HR of 0.98, 95% CI of 0.70-1.37 in those with ST]. The hazard of FN was significantly affected by the phase of treatment in AL/NHL (P
KW - Discontinuous interval of risk
KW - Epidemiology
KW - Event dependence
KW - Heterogeneity
KW - Pediatric cancer
KW - Repeated febrile neutropenia
UR - http://www.scopus.com/inward/record.url?scp=84866247062&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866247062&partnerID=8YFLogxK
U2 - 10.1179/1973947812Y.0000000002
DO - 10.1179/1973947812Y.0000000002
M3 - Article
C2 - 22759760
AN - SCOPUS:84866247062
SN - 1120-009X
VL - 24
SP - 155
EP - 160
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
IS - 3
ER -